前列腺癌中的免疫检查点疗法
Immune Checkpoint Therapies in Prostate Cancer.
作者信息
Goswami Sangeeta, Aparicio Ana, Subudhi Sumit K
机构信息
From the Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176.
Abstract
Advanced prostate cancer is the second leading cause of death from cancer in the United States. In the era of cancer immunotherapy, it was the first malignancy to demonstrate improved survival with a cancer-specific vaccine, thus proving that prostate cancer is an immune-responsive disease. However, the success with immune checkpoint therapies in metastatic prostate cancer has been limited to date with only a subset of patients experiencing clinical benefit. The relative lack of response could be attributed to patient selection based on clinical attributes and the tumor microenvironment. Here, we review the current data on immune checkpoint therapies in prostate cancer and propose future directions.
摘要
晚期前列腺癌是美国癌症死亡的第二大主要原因。在癌症免疫治疗时代，它是第一种通过癌症特异性疫苗显示出生存率提高的恶性肿瘤，从而证明前列腺癌是一种免疫反应性疾病。然而，迄今为止，免疫检查点疗法在转移性前列腺癌中的成功有限，只有一部分患者获得了临床益处。反应相对不足可能归因于基于临床特征和肿瘤微环境的患者选择。在此，我们回顾了目前关于前列腺癌免疫检查点疗法的数据，并提出未来的方向。
相似文献
1
Immune Checkpoint Therapies in Prostate Cancer.
Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176.
2
Immune Checkpoint Therapy in Melanoma.
Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183.
3
Immune Checkpoint Therapy in Head and Neck Cancers.
Cancer J. 2016 Mar-Apr;22(2):108-16. doi: 10.1097/PPO.0000000000000180.
4
The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Cancer J. 2016 Mar-Apr;22(2):96-100. doi: 10.1097/PPO.0000000000000175.
5
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933.
6
Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
Cancer J. 2016 Mar-Apr;22(2):101-7. doi: 10.1097/PPO.0000000000000179.
7
Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
Cancer J. 2016 Mar-Apr;22(2):81-91. doi: 10.1097/PPO.0000000000000178.
8
Immune Checkpoint Therapy in Renal Cell Carcinoma.
Cancer J. 2016 Mar-Apr;22(2):92-5. doi: 10.1097/PPO.0000000000000177.
9
Checkpoint inhibitors in breast cancer: hype or promise?
Clin Adv Hematol Oncol. 2016 Jun;14(6):392-5.
10
Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
Future Oncol. 2017 Feb;13(5):381-383. doi: 10.2217/fon-2016-0462. Epub 2016 Nov 25.
引用本文的文献
1
1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists.
RSC Med Chem. 2024 Feb 21;15(4):1210-1215. doi: 10.1039/d3md00746d. eCollection 2024 Apr 24.
2
Prostate cancer research: tools, cell types, and molecular targets.
Front Oncol. 2024 Mar 26;14:1321694. doi: 10.3389/fonc.2024.1321694. eCollection 2024.
3
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer.
Cancer Drug Resist. 2023 Sep 25;6(3):656-673. doi: 10.20517/cdr.2023.48. eCollection 2023.
4
Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications.
Curr Oncol. 2023 Aug 16;30(8):7638-7653. doi: 10.3390/curroncol30080554.
5
Prostate cancer cells synergistically defend against CD8 T cells by secreting exosomal PD-L1.
Cancer Med. 2023 Aug;12(15):16405-16415. doi: 10.1002/cam4.6275. Epub 2023 Jul 27.
6
Immunogenomic Landscape of Neuroendocrine Prostate Cancer.
Clin Cancer Res. 2023 Aug 1;29(15):2933-2943. doi: 10.1158/1078-0432.CCR-22-3743.
7
PD-L1 Up-Regulation in Prostate Cancer Cells by .
Front Cell Infect Microbiol. 2022 Jun 29;12:935806. doi: 10.3389/fcimb.2022.935806. eCollection 2022.
8
The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Cells. 2021 Nov 19;10(11):3247. doi: 10.3390/cells10113247.
9
Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments.
Cells. 2021 Nov 13;10(11):3155. doi: 10.3390/cells10113155.
10
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
Cancer Cell. 2021 Nov 8;39(11):1464-1478.e8. doi: 10.1016/j.ccell.2021.09.005. Epub 2021 Oct 15.
本文引用的文献
1
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
2
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
3
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.
4
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32. doi: 10.1038/pcan.2015.39. Epub 2015 Aug 11.
5
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res. 2015 Sep 1;21(17):3862-9. doi: 10.1158/1078-0432.CCR-15-0079. Epub 2015 Apr 29.
6
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
7
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
8
The future of immune checkpoint therapy.
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
9
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
10
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9.
Zotero 插件